Insulin down-regulates TRAIL expression in vascular smooth muscle cells both in vivo and in vitro

Journal of Cellular Physiology

Volumn 212, Issue 1, 2007, Pages 89-95

  Corallini, Federica ^a   Celeghini, Claudio ^a   Rizzardi, Clara ^a   Pandolfi, Assunta ^b   Di Silvestre, Sara ^b   Vaccarezza, Mauro ^c   Zauli, Giorgio ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF CASSINO AND SOUTHERN LAZIO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GLICLAZIDE; HEMOGLOBIN A1C; INSULIN; MESSENGER RNA; METFORMIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; ROSIGLITAZONE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ULTRARETARD; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL TONE; CELL CULTURE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; IMMUNOHISTOCHEMISTRY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES; VASCULAR RING; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

ANIMALS; CALCIUM-BINDING PROTEINS; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DOWN-REGULATION; HUMANS; INSULIN; MICROFILAMENT PROTEINS; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; RATS; RNA, MESSENGER; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

ANIMALIA; RATTUS;

EID: 34249901031     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21006     Document Type: Article

References (32)

1. Begum N, Ragolia L. 2000. High glucose and insulin inhibit VSMC MKP-1 expression by blocking INOS via p38 MAPK activation. Am J Physiol Cell Physiol 278:C81-C91.
2. Boulanger CM, Heymes C, Benessiano J, Geske RS, Levy BI, Vanhoutte PM. 1998. Neuronal nitric oxide synthase is expressed in rat vascular smooth muscle cells: activation by angiotensin II in hypertension. Circ Res 28:1271-1278.
3. Brophy CM, Knoepp L, Xin JD, Pollock JS. 2000. Functional expression of NOS 1 in vascular smooth muscle. Am J Physiol 278:H991-H997.
4. Buchwalow IB, Podzuweit T, Bocker W, Samoilova VE, Thomas S, Wellner M, Baba HA, Robenek H, Schnekenburger J, Lerch MM. 2002. Vascular smooth muscle and nitric oxide synthase. FASEB J 16:500-508.
5. Clarke N, Nebbioso A, Altucci L, Gronemeyer H. 2005. TRAIL: At the center of drugable anti-tumor pathways. Cell Cycle 4:914-918.
6. Fu M, Zhu X, Zhang J, Liang J, Lin Y, Zhao L, Ehrengruber MU, Chen YE. 2003. Egr-1 target genes in human endothelial cells identified by microarray analysis. Gene 315:33-41.
7. Gaston B, Drazen JM, Loscalzo J, Stamler JS. 1994. The biology of nitrogen oxides in the airways. Am J Respir Cell Mol Biol 149:538-551.
8. Gochuico BR, Zhang J, Ma BY, Marshak-Rothstein A, Fine A. 2000. TRAIL expression in vascular smooth muscle. Am J Physiol Lung Cell Mol Physiol 278:L1045-L1050.
9. Hasan RN, Phukan S, Harada S. 2003. Differential regulation of early growth response gene-1 expression by insulin and glucose in vascular endothelial cells. Arterioscler Thromb Vasc Biol 23:988-993.
10. Indolfi C, Torella D, Cavuto L, Davalli AM, Coppola C, Esposito G, Carriero MV, Rapacciuolo A, Di Lorenzo E, Stabile E, Perrino C, Chieffo A, Pardo F, Chiariello M. 2001. Effects of balloon injury on neointimal hyperplasia in streptozotocin-induced diabetes and in hyperinsulinemic nondiabetic pancreatic islet-transplanted rats. Circulation 103:2980-2986.
11. Kim H, Warthenby KA, Georgantas R, III, Wingard J, Civin C. 2002. Human CD34+ hematopoietic stem/progenitor cells express high levels of Fiip and are resistant to fas-mediated apoptosis. Stem Cells 20:174-182.
12. Kozlov AV, Sobhian B, Costantino G, Nohl H, Redl H, Bahrami S. 2001. Experimental evidence suggesting that nitric oxide diffuses from tissue into blood but not from blood into tissue. Biochim Blophys Acta 1536:177-184.
13. Lamhamedi-Cherradi S-E, Zheng S, Tisch RM, Chen YH. 2003. Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes. Diabetes 52:2274-2278.
14. LeBlanc HN, Ashkenazi A. 2003. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10:66-75.
15. Luscher TF, Barton M. 1997. Biology of the endothelium. Clin Cardiol 20:3-10.
16. Malinski T, Taha Z. 1992. Nitric oxide release from a signal cell measured in situ by a porphyrinic-based microsensor. Nature 358:676-678.
17. McCaffrey TA, Fu C, Du B, Eksinar S, Kent KC, Bush H, Kreiger K, Rosengart T, Cybulsky MI, Silverman ES, Collin T. 2000. High-level expression of Egr-1 and Egr-1 inducible genes in mouse and human atherosclerosis. J Clin Invest 105:653-662.
18. Mi QS, Ly D, Lamhamedi-Cherradi SE, Salojin KV, Zhou L, Grattan M, Meagher C, Zucker P, Chen YH, Nagle J, Taub D, Delovitch TL. 2003. Blockade of tumor necrosis factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD Mice. Diabetes 52:1967-1975.
19. Michowitz Y, Goldstein E, Roth A, Afek A, Abashidze A, Ben Gal Y, Keren G, George J. 2005. The Involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis. J Am Coll Cardiol 45:1018-1024.
20. Pandolfi A, Grilli A, Cilli C, Patruno A, Giaccari A, Di Silvestre S, De Lutiis MA, Pellegrini G, Capani F, Consoli A, Felaco M. 2003. Phenotype modulation in cultures of vascular smooth muscle cells from diabetic rats: Association with increased nitric oxide synthase expression and superoxide anion generation. J Cell Physiol 196:378-385.
21. Pritzker LB, Scatena M, Glachelli CM. 2004. The role of osteoprotegerin and tumor necrosis factor-related apoptosls-inducing ligand in human microvascular endothelial cell survival. Mol Biol Cell 15:2834-2841.
22. Schoppet M, Sattler AM, Schaefer JR, Hofbauer LC. 2006. Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis. Atherosclerosis 184:446-447.
23. Schwarz PM, Kleinert H, Forstermann U. 1999. Potential functional significance of brain-type and muscle-type nitric oxide synthase 1 expressed in adventitia and media of rat aorta. Arterioscler Thromb Vasc Biol 19:2584-2590.
24. Secchiero P, Gonelli A, Celeghini C, Mirandola P, Guidotti L, Visani G, Capitani S, Zauli G. 2001. Activation of the nitric oxide synthase pathway represents a key component of tumor necrosis factor-related apoptosis-inducing ligand-mediated cytotoxicity on hematologic malignancies. Blood 98:2220-2228.
25. Secchiero P, Vaccarezza M, Gonelli A, Zauli G. 2004a. TNF-related apoptosis-inducing ligand (TRAIL): A potential candidate for combined treatment of hematological malignancies. Curr Pharm Des 10:3673-3681.
26. Secchiero P, Zerbinati C, Rimondi E, Corallini F, Milani D, Grill V, Forti G, Capitani S, Zauli G. 2004b. TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 61:1965-1974.
27. Secchiero P, Candido R, Corallini F, Zacchigna S, Toffoli B, Rimondi E, Fabris B, Giacca M, Zauli G. 2006. Systemic TRAIL delivery shows anti-atherosclerotic activity in apoE-null diabetic mice. Circulation 114:1522-1530.
28. Steinhorn RH, Morin FCI, Russell JA. 1994. The adventitia may be a barrier specific to nitric oxide in rabbit pulmonary artery. J Clin Invest 94:1883-1888.
29. Van Zwieten PA. 1997. Endothelial dysfunction in hypertension. A critical evaluation. Blood Press, Suppl. 67-70.
30. Zauli G, Secchiero P. 2006. The role of the TRAIL/TRAIL-receptors system in hematopoiesis and endothelial cell biology. Cyt Growth Fact Rev 17:245-257.
31. Zauli G, Pandolfi A, Gonelli A, Di Pietro R, Guarnieri S, Ciabattoni G, Rana R, Vitale M, Secchiero P. 2003. TNF-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells. Circ Res 92:732-740.
32. Zhang XD, Nguyen T, Thomas WD, Sanders JE, Hersey P. 2000. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett 482:193-199.